Participants in this study will receive a drug called ribociclib with the endocrine therapy of your physician’s choice. Ribociclib is taken as a pill. Endocrine therapy is taken as a pill or given as a shot. You will have tests, exams and procedures that are part of your regular care and for study purposes. Also, as part of routine care, you will be checked every 4 to 12 weeks to make sure your cancer hasn’t come back. You will receive ribociclib combined with endocrine therapy for up to 3 years. After that you will continue endocrine therapy alone for another 2 years (5 years total) as part of your regular care.

Participants will be required to: - receive ribociclib along with standard endocrine therapy drugs - have blood drawn - imaging scans (CT, PET-CT, bone scans, mammograms, MRI) - keep a medication diary - optional biopsy - ECG-a test that looks at the way your heart beats - ECHO-a test that looks at the way your heart pumps

This study aims to measure child eating behavior at home. Parents will video record their child eat 3 meals at home using a smart phone device and then take pictures of food storage locations (e.g., fridge, pantry). Videos will be coded for child eating behaviors. Parents will complete baseline and follow-up questionnaires. Children will wear an activity watch (like a Fitbit) for 1 week. In addition to these study procedures, there is an optional urine sample collection for children in order to study urinary metabolites as a marker of diet.

You will be asked to video record your child eating 3 meals at home and to take photos of food storage locations in your home (e.g., fridge, pantry).

$75 and an optional $25 for completing the urine sample collection

The purpose of this study is to determine how effective and safe axi-cel is compared to standard of care, specifically chemo-immunotherapies, and use this information to determine the best choice of treatment in Subjects with Relapsed/Refractory Follicular Lymphoma

Attend all study visits receive study drug or SOChave blood drawn for various testsECHO or MUGA, ECG, PET/CT, and MRI if neededbone marrow biopsy if neededComplete questionnaires

This study is being conducted to determine the efficacy, safety and tolerability of subcutaneous (applied under the skin) dosing of an experimental drug named ABC008 in subjects with inclusion body myositis (IBM).

Eligible subjects will be randomized into four different groups with one of two dose levels of the study drug or matching placebo. The study drug will be given by injection every eight weeks. At the safety follow-up visit, subjects will have the option to enroll in a long-term extension study.

$1137

Voluntary research study is to test INBRX-101 as an experimental drug to treat patients with alpha-1 antitrypsin deficiency. The goal of this study is to evaluate the safety and study the therapeutic effects of INBRX-101 in AATD emphysema patients when compared with current approved AATD therapy with A1PI.

You will visit the study site up to a total of 37 times for blood sampling, computed tomography (CT) scan, lung function tests, electrocardiograms (ECGs), study drug administration and questionnaire completion.

Unknown at this time

The goal of this study is to understand the use of dating apps in emerging adults (ages 18-29 years old). Using an online survey, participants will be asked a series of questions about their well-being, romantic relationship history, and about their use of dating apps.

You will be asked to take a brief, 15-25 minute online survey, and you may be asked to upload a few screenshots from your phone.

Over the past few decades, the social world of teens has been transformed by the use of digital technology. This study will examine associations between digital media use and emotions in adolescents' daily lives.Youth and their parent will complete questionnaires and semi-structured clinical interviews regarding the youth’s emotions, social experiences, and possible anxiety symptoms. For 10 consecutive days, youth will complete one computerized task once per day and four mini questionnaires via the Wear-It app on the youth's mobile device.Some youth will also participate in a lab visit that will last approximately two hours. Six months later, all youth will be asked to repeat one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device.One year after enrollment, participants will complete final questionnaires, interviews, one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device. Some youth will also participate in a lab visit that will last approximately two hours.

Over the past few decades, the social world of teens has been transformed by the use of digital technology. This study will examine associations between digital media use and emotions in adolescents' daily lives.Youth and their parent will complete questionnaires and semi-structured clinical interviews regarding the youth’s emotions, social experiences, and possible anxiety symptoms. For 10 consecutive days, youth will complete one computerized task once per day and four mini questionnaires via the Wear-It app on the youth's mobile device.Some youth will also participate in a lab visit that will last approximately two hours. Six months later, all youth will be asked to repeat one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device.One year after enrollment, participants will complete final questionnaires, interviews, one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device. Some youth will also participate in a lab visit that will last approximately two hours.

$495

In this project, participants will perform experiments where they will be asked to look at salient virtual targets and make reaching movements to those targets, while ignoring other visual stimuli presented to them.

During this study, we will ask you to come to our laboratory located in 23 Recreation Building, Penn State University, on a single day.We will ask you to perform an eye-hand coordination task using a robot. You will sit in a modified chair and grasp a handle that permits you to move your hand leftward, rightward, towards and away from your body. A display system will project visual targets into the same plane as your hands, which will allow you to interact virtually with the visual targets. These targets will be either bright or dark and you will be instructed to look at some of these targets (while ignoring others) and make reaching movements to some of these targets.

20

Most attempts to quit smoking end in relapse, or a return to regular smoking. One of the biggest threats to cessation is a lapse (i.e., any cigarette use during a quit attempt). Thus, characterizing why lapses occur is essential to understanding and preventing smoking relapse. Functional magnetic resonance imaging (fMRI) is a promising method for characterizing the psychological processes that lead to smoking lapses because it provides a way to measures patterns of brain activity thought to reflect relevant mental processes as they change over time. However, methodological issues have hindered the ability to capitalize on this potential and prevented an understanding of how brain activity and corresponding psychological processes unfold in the critical moments that immediately precede a smoking lapse. The proposed project will address this knowledge gap using a novel fMRI paradigm adapted from a well-validated behavioral lapse task. The goals of the project are to characterize changes in brain activity that lead up to a lapse and to investigate how these changes are related to concurrent affect and subsequent cigarette use.

There will be two in-person visits, both will involve completion of computerized questionnaires and one will involve completing and MRI scan

175

This is an interview study that will examine how people with and without ADHD tell stories. Eligible participants will be asked to attend a virtual televisit where they will tell three stories according to prompts given by study staff. We are recruiting both men and women for this study so we can determine if gender affects storytelling ability.

There will be one virtual visit on Zoom lasting approximately one hour. Participants will complete eligibility questionnaires, then eligible participants will be asked to tell three stories based on prompts from an investigator and complete one additional questionnaire.

$15

This is an open-label drug study of SerpinPC (a subcutaneously administered drug) for patients with severe hemophilia A or moderately severe to severe Hemophilia B. The study consists of 3 parts after an observation phase of 12-24 weeks: 24 week justification phase, 24 week confirmatory phase & 24 week extension phase.

This is a subcutaneous drug treatment clinical trial with an observation period of up to 24 weeks, pre-dosing/dosing period of 8 visits on site or phone calls & an extension period of 6 visits.

$75.00 travel reimbursement per visit

A 16 week double blind treatment period to investigate the safety and effectiveness of 3 doses of the study drug vs placebo for endometriosis related pain.

There will be 8 onsite visits and 2 phone visits, blood will be drawn at the onsite visitsThere is an ediary that must be completed every dayStudy exams include a TVU ultrasound, ECG, vital signs, urine pregnancy tests and blood work

$1477.00

This study is being done to learn if it is safe to add naxitamab to standard therapy during the Induction phase of care for patients with newly diagnosed high-risk neuroblastoma. Naxitmab is an immunotherapy agent which trains your immune system to target your tumor in a more specific way than chemotherapy does.

This study has 3 phases- screening, treatment, and follow up. If you join the study, during screening we will test a sample of your tumor along with your blood. The tumor sample will be obtained at the same time as you are having surgery or a biopsy. Other testing will be done to make sure you are eligible to receive treatment. If you are eligible for treatment, you will receive five 21 day cycles of anti-cancer medication (induction chemotherapy) along with naxitamab. You will have to stay in the hospital to receive this treatment for at least 6 days of each 21 day cycle. If your screening testing also shows a certain genetic change in your tumor, we may also add a medication that is targeted at that change. If your tumor does not respond adequately to the initial cycles, we may give up to three additional 21 day cycles of chemotherapy with naxitamab. You will also have procedures at certain timepoints during induction that are standard of care for your tumor. These include collecting stem cells for use later in your therapy after Cycle 2. After Cycle 4, you will have surgery to remove as much of the tumor as possible. The treatment phase will last about 8 months, after which you will be in follow up. During your time on the study, we will ask to collect research samples of blood, bone marrow, and tumor. We will be monitoring your progress and health throughout your time on treatment and in follow up.

This study looks at the relationship between motor control via. arm movement and visual stimuli. After participating in brief calibration protocol for the eye tracking system, participants will be moving a robotic handle to interact with visual stimuli during various tasks. Participants will spend approximately 2 hours in the lab.

There will be one approximately 2-hour visit. They will then be asked to complete 20-25 blocks of hand movements while looking at a moving virtual stimulus with a large visual background. Participants will receive regular breaks during the experiment.

$20

This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety profile of barzolvolimab (CDX-0159) in patients with active EoE. The study will enroll approximately 60 patients.This study consists of four distinct phases lasting approximately a year. Each patient will receive 1 dose (2 injections) every 4 weeks. The participants will be required to sign the informed consent before any procedures are performed. If eligible for screening, they will need to have standard lab tests (blood and urine), EKG, pregnancy test if applicable, and tests for COVID-19. They will also be required to have EGD with biopsies done during the screening period and at weeks 12 and 28. If eligible to continue, the participants will be randomized on day 1, when they will receive their first treatment. They will be required to come back to the clinic in two weeks and four weeks after that. They will have to complete the e-diary questionnaires at home.

There will be ten in person visits, including screening, placebo-controlled treatment and active (open label) treatment. In addition, there are four follow up visits every 4 weeks. The participants must sign the informed consent. There are going to have vital signs checked at every visit. Some visits have a physical exam. There are blood tests, urine tests, ECG, and COVID -19 tests done. The participants will have EGD procedure with biopsies at screening, and at 12 and 28 weeks of treatment. There will be four study treatments administered in the clinic. The concomitant medications, and adverse events will be monitored and documented. Serum and urine pregnancy tests will be performed if applicable. Participants will be asked to complete electronic diary daily.

$75 per visit; you may receive travel reimbursement $50, and $50 meal compensation for visit 1, 2, 5, 7, and 9

The reproducibility, reliability, and validity of saliva collection techniques is an important issue that needs to be addressed to achieve consistency in the emerging field of mitochondrial psychobiology. The objective of the current study is to increase scientific rigor by utilizing robust and well-controlled methods in the collection and testing of saliva samples. Given the non-invasive and convenient nature of saliva collection, it is likely that research using saliva-derived cell-free mitochondrial DNA (cf-mtDNA) will increase. Therefore, to ensure that the results obtained from the current study are trustworthy and meaningful, we are proposing a small, highly controlled randomized study design that will integrate three methods of saliva collection. The study will adopt a rigorous and systematic approach to data collection, analysis, and interpretation. Through the implementation of these methods, we seek to achieve a higher degree of accuracy and reliability in cf-mtDNA saliva-based measurements.

Each participant will be asked to collect 3 randomized saliva samples (i.e., one static Salivette®, one active Salivette®, and either a second active Salivette® or a passive drool) upon awakening for 10 business days. All collection materials be pre-labeled with the day, type of sample, and order to make it easy for participants to quickly and accurately deposit samples upon awakening. Once saliva samples are collected, participants will be asked to promptly return the samples to the provided plastic bag and store the bag in their at-home freezers. All samples will be stored there until the end of the 10-day study. After the saliva is returned to the freezer, participants will complete a short (3-5 min) morning survey on the provided mobile device which has been pre-loaded with the M2C2 application. The morning survey asks questions about sleep, morning outlook, and anticipatory stress and positive experiences. In the evenings, participants will be prompted (via banner notification on screen and audible beep) to complete a slightly longer (8-10 min) survey. This survey asks questions about the respondent’s daily experiences (stressors, mood, physical symptoms). Within the application, there are three brief, objective cognitive tasks. Upon completion of the 10-day protocol, respondents will return the mobile device and saliva samples. Participants may bring all saliva samples back to the lab during regular business hours, or they may schedule a time for a member of the study team to pick up the samples. Depending on the distance between the laboratory and the participant’s home, the need for ice packs will be assessed on an individual basis.

50

People with narrowed blood vessels in their legs can only walk a short distance before needing to sit down due to pain in their calf muscles. Most of these patients do not follow their heart doctor's advice to walk at home because it hurts. A therapy that does not involve painful walking would be ideal for these patients to begin to treat their disease so they can eventually walk with less discomfort. We will ask patients with peripheral artery disease (PAD) to place both feet into inflatable ankle splints 30 minutes a day for 4 weeks to passively stretch their calf muscles. Before and after this 4-week program, we will measure the health and size of their leg blood vessels, the length, and function of their calf muscles and tendons, and how long they can walk without pain. We will also closely track their joint and foot movements and calf muscle oxygen levels while they walk down a hallway. People with and without risk factors for heart disease are also eligible for this study to compare differences in vascular and muscular health to patients with PAD. Volunteers without a PAD diagnosis or poor leg circulation will not undergo the 4-week stretch and no-stretch interventions.

Peripheral artery disease (PAD) and poor leg circulation patients:-4 visits to University Park Clinical Research Center ~3 hours per visit-1 blood draw-Wear a calf muscle stretching device for 30-min a day, 5 days a week, for 4 weeks and 4 weeks of no stretching-Several muscle and vascular ultrasound measurements-Walking performance tests on and off the treadmill-Wear a smartwatch to monitor physical activity during each 4-week stretch or no stretch interventionParticipants with and without risk factors for heart disease:-2 visits to University Park Clinical Research Center within the same week lasting ~3 hours per visit-Not diagnosed with PAD or poor leg circulation-1 blood draw-Several muscle and vascular ultrasound measurements-Walking performance tests on and off the treadmill

PAD participants can receive up to $450 in compensation. Participants with and without heart disease risk factors (non-PAD participants) will receive $50 for their participation.

This study will examine neural reactivity to stress in young adults who use alcohol and cannabis and link these responses to behaviors in everyday life.

You will be asked to complete the following:1) An in-lab intake appointment for interviews and questionnaires2) An in-lab neuroimaging training session and scan + smartphone-based training session3) Three separate 14-day bursts (total of 42 days) of smartphone-based reporting in daily life4) A follow-up visit after the first 14-day burst5) 6-month follow-up appointment for interviews and questionnaires6) 12-month follow-up appointment for interviews and questionnaires

717

During the COVID-19 pandemic, Asian Americans have faced a rise in overt racism, with thousands of hate incidents reported. This has had a bigger impact on young Asian American adults, leading to emotional distress and health problems. A theory by Harrell suggests that experiencing racial discrimination can harm mental and physical well-being due to stress. Past studies have shown a connection between racial discrimination stress and health issues like obesity and mental disorders. However, there's a need to understand the cultural and emotional factors involved. This research aims to explore how racial discrimination affects Asian Americans' food choices by looking at stress responses and cultural influences. Using surveys, experiments, psychophysiology, and virtual reality, the study will investigate how cultural identity affects stress reactions and subsequent food decisions after racial discrimination experiences.

Hello,We are recruiting Asian Americans with Japanese, Chinese, or Korean heritage for a paid research study.We want to understand how racism affects food choice in a virtual reality (VR) environment. To participate in this study, you will need to complete an informed consent form, and answer questions prior to your arrival at the lab. You will have to come to the lab to watch a video of anti-Asian racism incidents that happened during the COVID-19 pandemic, and answer questions before and after the video. Last, you will make food choices in the VR environment. Participation will require three hours or more of fasting before arrival at the lab.You will be paid $25 in a gift card for your participation. If you come to the lab but do not complete the study, you will still be paid.Please continue to the next page to read the informed consent if you are interested in participating. If you are not, please exit this page.<<LINK TO REDCap SURVEY HERE>>

$25 gift card

This is a Phase 3 study of single-dose SPK-8011 AAV gene therapy in combination with immunomodulation. Patients will receive a one-time dose of SPK 8011, three weeks of methylprednisolone & then will be followed for safety & efficacy per study schedule.

1) Screening period of < 8wks.-1 visit2) Lead-in for >24 wks.-1 visit3) Pre-dose day -24-1 visit4) Dosing-Day 1 & Day 2-2 visits5) Primary study (15 mos.)-37 visits6) Long term follow-up approx. 9 yrs.-20 visitsSome visits may be done via home health when a physical isn't required.

$75.00 travel reimbursement per visit

This trial is comparing outcomes of cisplatin eligible vs cisplatin ineligible high grade urothelial cancer patients treated with accelerated therapy vs gemcitabine and durvalumab followed by surgery.

Participants will need to complete all study visits, agree to having surgery and to make sure to tell the study team if they are having any side effects.

To see how ziltivekimab taken once monthly versus placebo, both added to standard of care, in reducing the risk of cardiovascular death and heart failure events in participants with heart failure iwht mildly reduced or preserved ejection fraction and systemic inflammation.

Return for on site visits 14 times, participate in 6 phone calls, complete questionnaires, blood samples taken at each on-site visit, electrocardiogram completed on 5 visits, injection of study medication.

approximatley $1,120

The purpose of this voluntary research study is to collect measurements of related heart function using an insertable cardiac monitor (ICM) in heart failure patients. Commercially available ICMs are used for the detection of abnormal heart rhythms and long-term monitoring. The ICM does not provide therapy, but for this study has various sensors which offer added heart failure diagnostic features. Patients will be required to undergo the investigational implantable cardiac defibrillator, attend 6 clinical visits, agree to wear a mobile monitor which is similar to a cell phone with a downloaded application named myLUX, tell the study doctor if any planned or unplanned visits to the hospital for any reason, admission to the hospital for heart failure, and/or if they have been treated with an IV medication for heart failure in the emergency room, urgent care or clinic.

The purpose of this voluntary research study is to collect measurements of related heart function using an insertable cardiac monitor (ICM) in heart failure patients. Commercially available ICMs are used for the detection of abnormal heart rhythms and long-term monitoring. The ICM does not provide therapy, but for this study has various sensors which offer addedheart failure diagnostic features. You will be required to undergo the investigational implantable cardiac defibrillator, attend 6 clinical visits, agree to wear a mobile monitor which is similar to a cell phone with a downloaded application named myLUX, tell your study doctor if you have any planned or unplanned visits to the hospital for any reason, admission to the hospital for heart failure, and/or if you have been treated with an IV medication for your heart failure in the emergency room, urgent care or your clinic.

$250

This study design is a survey that collects information about students' active level and supplement use, with an emphasis on creatine. The difference between contact and non-contact athletes will be examined, in addition to people who are considered inactive/low activity. This will help provide information of how physical activity related supplementation use affects cognition in different populations, with varying amounts of neurotrauma.

All participants will complete a digital survey that provides information about their dietary supplementation and physical activity habits. As part of the survey, participants will be allowed to indicate their interest and availability to come to a laboratory setting to complete a brief batter of neurocognitive tests.

The purpose of this study is to assess if healthy adults speak at a consistent speaking rate when asked to read a standard passage or answer an open ended prompt.

There will be 2 visits that each take approximately 20 minutes. We will meet in person or via Zoom. At each visit you will be asked to read three paragraphs and answer some open ended questions/prompts.

The concreteness effect is the finding that individuals are faster and more efficient at processing concrete words (e.g., "dog") than abstract words (e.g., "wisdom"). The study will investigate the presence and strength of the concreteness effect in neurologically intact older adults. This data will be used as a control comparison for a group of people with aphasia, a language disorder that commonly results from left hemisphere stroke.

Participants will be asked to complete language and cognition tests that measure attention, memory, problem solving, and language processing on the computer. Participants will be asked to complete two Zoom sessions, each lasting approximately 1.5 hours.

30

The purpose of this voluntary research study is to evaluate potential new anticancer to treat people with tumors similar to yours. This study will provide information about the safety, the ability of your body to accept the study drug(s), the amount of study drug(s) and/or break-down products in your blood, and your body’s reaction to the study drug(s). Participants will be required to take study medication, have blood drawn, and have imaging tests such as CT, MRI, ECG, MUGA, ECHO, and bone scans.

Participants in the expansion stage will receive study treatment, imaging exams (ECHO, MUGA, ECG, CT, MRI, bone scans), blood draws, tumor assessments, and tumor tissue samples.

Sound symbolism is the idea that the sound of a word alone can convey its meaning. Aphasia is a language impairment, occurring most often as a result of a stroke. There is some evidence that sound-symbolic language is preserved in stroke patients. Studies in this protocol will investigate the extent to which this is so, and whether sound-symbolic language could be a rehabilitation strategy for aphasia.

We will ask you to listen to real words and non-words and make judgements about them. We may also ask you to complete some tests of language ability. The total time commitment may be up to four hours but will be split into two sessions.

Amount varies depending on the study

The purpose of this study is to understand the neural and behavioral mechanisms subserving social and non-social risky decision making.

There will be one in-person lab visit where you will play a decision-making game, while having an fMRI scan.

$31.25

At this time, there is no treatment available for celiac disease diagnosis. The study is designed to test safety, tolerability and pharmacokinetics of KAN-101 to treat celiac disease diagnosis. We will participate only in the Part B study portion. Part B is a Phase 2, double-blind, placebo-controlled, parallel design study to characterize the biomarker response (plasma IL-2) in peripheral blood following gluten challenge, safety, tolerability, and pharmacokinetics (how does drug move in the body) of KAN-101 in adult participants (18 to 70 years inclusive) with histology-confirmed celiac disease. Participants will be randomized 1:1:1:1, where one arm is placebo, and other arms are different drug doses. The study consists of a screening period to determine eligibility to participate, a run-in phase where participants are gluten-challenged for one day, a treatment phase where participants will receive a seven-days treatment, and observation period lasting 358 days where participants will have a post-dose gluten challenge on Day 15, and three other time-points. The study aims to enroll 120 subjects across all sites. Participants will be asked to come for the clinic visit, to have gluten challenged done in the clinic, and treatment infusions in the clinic. There are two follow-up visits planned. The participants will have required EGD w/biopsy, and will be offered optional EGD biopsy study, that collects specimens at two time points. All participants will have a blood work done to access eligibility for participation, and to test for drug PK and biomarkers in the response of the treatment. They will also have EKG and physical examinations, vital signs checked during the clinic visits. They will complete questions for patient reported symptoms. Eligible women participants will be tested for pregnancy, and contraception will be discussed for both male and female participants.

Participants will be asked to come to the clinic visits for the screening, gluten challenge, treatment visits and follow up. During the visits, participants will have blood tests done to determine eligibility for the study, or the test how the drug moves through the body and whether it works to dampen the celiac disease symptoms. The patients will have EGD with biopsies procedure done in the endoscopy suite, and they will be offered optional biopsies study. The gluten challenge will consist of drinking a glass of water containing 9g pre-prepared gluten challenge mix. The participants will be observed for four hours. The treatment is done via infusion in the clinic over 30-minutes,and observed for four hours after that. The participants will have to come in for three treatment visits within seven days (days 1, 4, and 7).

$975